Technical Analysis for IPA - ImmunoPrecise Antibodies Ltd.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.42 | -12.47% | -0.06 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% |
| Alert | Time |
|---|---|
| Gap Down Partially Closed | 1 day ago |
| Gap Down Closed | 1 day ago |
| Gapped Down (Partial) | 1 day ago |
| Down 5% | 1 day ago |
| Down 3% | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 12/12/2024
ImmunoPrecise Antibodies Ltd. Description
ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Immunology Antibodies Monoclonal Antibody Antibody Cloning Screening
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.6 |
| 52 Week Low | 0.4016 |
| Average Volume | 535,850 |
| 200-Day Moving Average | 1.13 |
| 50-Day Moving Average | 0.62 |
| 20-Day Moving Average | 0.56 |
| 10-Day Moving Average | 0.53 |
| Average True Range | 0.08 |
| RSI (14) | 33.33 |
| ADX | 26.51 |
| +DI | 14.92 |
| -DI | 26.66 |
| Chandelier Exit (Long, 3 ATRs) | 0.47 |
| Chandelier Exit (Short, 3 ATRs) | 0.63 |
| Upper Bollinger Bands | 0.67 |
| Lower Bollinger Band | 0.44 |
| Percent B (%b) | -0.12 |
| BandWidth | 40.42 |
| MACD Line | -0.04 |
| MACD Signal Line | -0.03 |
| MACD Histogram | -0.0084 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.54 | ||||
| Resistance 3 (R3) | 0.54 | 0.51 | 0.52 | ||
| Resistance 2 (R2) | 0.51 | 0.48 | 0.51 | 0.51 | |
| Resistance 1 (R1) | 0.46 | 0.46 | 0.45 | 0.46 | 0.50 |
| Pivot Point | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 |
| Support 1 (S1) | 0.39 | 0.40 | 0.37 | 0.38 | 0.33 |
| Support 2 (S2) | 0.35 | 0.38 | 0.35 | 0.33 | |
| Support 3 (S3) | 0.31 | 0.35 | 0.32 | ||
| Support 4 (S4) | 0.30 |
